#	Pagina
attuale pagina	/open-h2020/projects/217808/index.html
-1	/open-h2020/projects/200072/results.html
-2	/open-fp7/projects/188566/index.html

Opendata, web and dolomites

NUTRI-NEED SIGNED

Final development, clinical validation and launch preparation of NL01, an innovative health ingredient for supplements, food products and foods for special medical purposes

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

NUTRI-NEED project word cloud

Explore the words cloud of the NUTRI-NEED project. It provides you a very rough idea of what is the project "NUTRI-NEED" about.

company proven register campina kg components demand purposes industry plant life launch revenues ingredients entry eacute people data huge perform 115 industrial young medical supplements small licensing preclinical friesland medium patients projected ec function inclusion risk changer commercial healthy cumulative claims supports isolated foods 46x efsa nutrileads 2026 elderly supporting isolation dynamic health million shown market food clinical adults dsm licence nl01 grant benefits safety obtain status generate deals representing complete danone immune functional advice registration containing claim crop fresenius works approved infection ingredient dietary infections abbott track humans first leaders companies gt resistance live population 250 regulatory game clinically proprietary nestl consumers desired

Project "NUTRI-NEED" data sheet

The following table provides information about the project.

Coordinator	NUTRILEADS BV Organization address address: BRONLAND 12 N city: WAGENINGEN postcode: 6708 WH website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	https://nutrileads.com/investors/
Total cost	3˙567˙000 €
EC max contribution	2˙496˙900 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-06-01 to 2020-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	NUTRILEADS BV NUTRILEADS BV Organization address address: BRONLAND 12 N city: WAGENINGEN postcode: 6708 WH website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (WAGENINGEN)	coordinator	2˙496˙900.00

Map

Project objective

People want to live a long and healthy life and there is a huge demand for food products to enable this. Among consumers, the most desired health benefits in food products and supplements are ‘supports immune function’ and ‘increases resistance to infections’.

NutriLeads is a dynamic Health Ingredients company developing crop-derived food ingredients with clinically proven health benefits. With its proprietary lead ingredient NL01, having completed preclinical data and proven safety in humans, NutriLeads is on track to become the first company to launch an ingredient with an approved health claim for supporting immune function and increasing infection resistance. Targeted end-users of NL01 containing food products (dietary supplements, medical- and functional foods) are young adults, adults, elderly and patients, aiming to support their health and immune status.

Nutrileads selected a common crop from which NL01 can be isolated, a game-changer for its commercial success,and developed the isolation process for NL01 up to small scale industrial plant production. In this project, Nutrileads will perform medium scale-up of the production process to 250 kg. Nutrileads will complete the data package for NL01 with a clinical study in a relevant population with increased infection risk to support the health claims on NL01, register NL01 as ‘Novel Food’ and obtain European Food Safety Authority (EFSA) regulatory advice on registration as ‘Food for Specific Medical Purposes’.

NutriLeads will generate revenues from out-licensing NL01 to large companies in the food industry. Market leaders Abbott, Nestlé, Friesland Campina, Danone, Fresenius regularly in-licence components for inclusion in their products; Nestlé and DSM have already shown interest in Nutrileads’ products. Nutrileads works towards market entry and first deals during or directly after this project with a projected best-case cumulative revenues of €115 million in 2026, representing >46x the EC grant.

Deliverables

List of deliverables.
NL01 brand & logo	Websites, patent fillings, videos etc.	2019-08-01 13:00:52

Take a look to the deliverables list in detail: detailed list of NUTRI-NEED deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NUTRI-NEED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NUTRI-NEED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.